ALK and non-small cell lung carcinoma: The toxicity profile should be considered before the use of any TKI in the management of ALK-rearranged NSCLC, such as myalgia, edema, hepatotoxicity, interstitial lung disease/pneumonitis and bradycardia with alectinib and respiratory symptoms [264,265], vision change, amylase and lipase elevation, hypertension and similarly bradycardia with brigatinib.